サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1696208

世界のマルチオミクス市場 - 2025年～2033年

Global Multi-omics Market - 2025-2033

出版日
ページ情報
英文 180 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=145.28円
世界のマルチオミクス市場 - 2025年～2033年
出版日: 2025年03月25日
発行: DataM Intelligence
ページ情報: 英文 180 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

世界のマルチオミクス市場は、2024年に32億5,000万米ドルに達し、2033年には332億5,000万米ドルに達すると予測され、予測期間2025-2033年のCAGRは26.1%で成長します。

マルチオミクスは、様々なオミクス技術を統合した学際的アプローチであり、様々な分子層からのデータを分析することで、バイオマーカーの発見、疾病メカニズムの解明、個別化医療の進展を支援します。

世界のマルチオミクス市場は、精密医療の採用、創薬研究、シーケンス技術により大きな成長を遂げています。主な促進要因としては、統合された生物学的データ解析の需要、政府からの資金援助、ヘルスケアとバイオテクノロジーへの応用などが挙げられます。北米は強力な研究インフラにより市場をリードしているが、アジア太平洋は有利な地域として浮上しています。サーモフィッシャーサイエンティフィック、イルミナ、QIAGENなどの大手企業がこの分野のイノベーションを推進しています。

市場力学：

促進要因と抑制要因

精密医療の普及

世界のマルチオミクス市場を牽引しているのは、個人の遺伝子、プロテオーム、代謝プロファイルをより深く理解できる精密医療への注目の高まりです。政府やヘルスケア機関は、がんや神経疾患のような複雑な疾患に対する個別化治療を開発するため、マルチオミクス研究に多額の投資を行っています。人工知能とバイオインフォマティクスの融合は、創薬と患者固有の治療戦略を加速させています。

例えば、2025年1月、3Dゲノミクス技術のパイオニアであるEnhanc3D Genomics社は、創薬の精度を高めるための統合マルチオミクス・ソリューション群を発表しました。同社独自の3Dゲノミクス・プラットフォームに基づくこのソリューションは、創薬・開発プロセス全体の意思決定をサポートする包括的なエンド・ツー・エンドのソリューションをパートナーに提供します。

データの複雑性と統合

世界のマルチオミクス市場は、ゲノミクス、トランスクリプトミクス、プロテオミクス、メタボロミクスから膨大な異種データが生成されるため、データの複雑性と統合による課題に直面しています。このため、意味のある解釈のための高度な計算ツール、プラットフォーム間の標準化、データベース間の相互運用性が必要となります。データの正確性、再現性、スケーラビリティを確保するには、高性能なコンピューティングと高度なアルゴリズムが必要であり、小規模な研究機関や臨床アプリケーションの利用には限界があります。

目次

第1章 市場イントロダクションと範囲

  • 報告書の目的
  • 調査範囲と定義
  • 調査範囲

第2章 エグゼクティブの洞察と重要なポイント

  • 市場のハイライトと戦略的ポイント
  • 主な動向と将来の予測
  • 製品とサービス別の抜粋
  • テクノロジー別スニペット
  • アプリケーション別スニペット
  • エンドユーザーによる抜粋
  • 地域別スニペット

第3章 市場力学

  • 影響要因
    • 促進要因
      • 精密医療の導入増加
      • シーケンシング技術の進歩
    • 抑制要因
      • データの複雑さと統合
      • 規制と倫理に関する懸念
    • 機会
      • クラウドベースのマルチオミクスソリューションの開発
    • 影響分析

第4章 戦略的洞察と業界展望

  • 市場のリーダーと先駆者
    • 新たな先駆者と著名なプレーヤー
    • 最大の売上を誇るブランドを確立したリーダー
    • 確立された製品を持つ市場リーダー
  • CXOの視点
  • 最新の開発とブレークスルー
  • ケーススタディ/進行中の調査
  • 規制と償還の情勢
    • 北米
    • 欧州
    • アジア太平洋地域
    • ラテンアメリカ
    • 中東・アフリカ
  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 特許分析
  • SWOT分析
  • アンメットニーズとギャップ
  • 市場参入と拡大のための推奨戦略
  • シナリオ分析ベストケース、ベースケース、ワーストケースの予測
  • 価格分析と価格市場力学
  • 主要なオピニオンリーダー

第5章 製品・サービス別

  • 機器
  • 消耗品と試薬
  • サービス

第6章 技術別

  • ゲノミクス
  • トランスクリプトミクス
  • プロテオミクス
  • メタボロミクス
  • エピゲノミクス

第7章 用途別

  • 医薬品の発見と開発
  • 精密医療
  • 臨床診断
  • バイオテクノロジーと産業応用

第8章 エンドユーザー別

  • 製薬・バイオテクノロジー企業
  • 調査機関および学術センター
  • 病院・クリニック
  • CROとCDMO

第9章 地域別：市場分析と成長機会

  • 北米
    • 地域特有の重要事項市場力学
      • 米国
      • カナダ
  • 欧州
    • 地域特有の重要事項市場力学
      • ドイツ
      • 英国
      • フランス
      • スペイン
      • イタリア
      • その他欧州地域
  • ラテンアメリカ
    • 地域特有の重要事項市場力学
      • メキシコ
      • ブラジル
      • アルゼンチン
      • その他ラテンアメリカ地域
  • アジア太平洋地域
    • 地域特有の重要事項市場力学
      • 中国
      • インド
      • 日本
      • 韓国
      • その他アジア太平洋地域
  • 中東・アフリカ
    • 地域特有の重要事項市場力学

第10章 競合情勢と市場ポジショニング

  • 競合状況の概要と主要な市場プレーヤー
  • 市場シェア分析とポジショニングマトリックス
  • 戦略的パートナーシップ、合併、買収
  • 製品ポートフォリオとイノベーションにおける主な発展
  • 企業ベンチマーク

第11章 企業プロファイル

  • BD（Becton, Dickinson and Company）
    • 会社概要
    • 製品ポートフォリオ
      • 製品説明
      • 製品の主要業績評価指標（KPI）
      • 過去および予測の製品販売
      • 製品販売量
    • 財務概要
      • 会社の収益
      • 地域別収益分配
      • 収益予測
    • 主な発展
      • 合併と買収
      • 主な製品開発活動
      • 規制当局の承認等
    • SWOT分析
  • Thermo Fisher Scientific Inc
  • Illumina, Inc
  • Danaher Corporation
  • Bruker Corporation
  • QIAGEN N.V
  • Agilent Technologies, Inc
  • Genedata
  • Shimadzu Corporation
  • Element Biosciences

第12章 前提条件と調査手法

  • データ収集方法
  • データの三角測量
  • 予測技術
  • データの検証と検証

第13章 付録

目次
Product Code: BT7715

The global multi-omics market reached US$ 3.25 Billion in 2024 and is expected to reach US$ 33.25 Billion by 2033, growing at a CAGR of 26.1% during the forecast period 2025-2033.

Multiomics is a multidisciplinary approach that integrates various omics technologies, aiding in the discovery of biomarkers, understanding disease mechanisms, and advancing personalized medicine by analyzing data from various molecular layers.

The global multiomics market is experiencing significant growth due to precision medicine adoption, drug discovery research, and sequencing technologies. Key drivers include demand for integrated biological data analysis, government funding, and healthcare and biotechnology applications. North America leads the market due to strong research infrastructure, while Asia-Pacific is emerging as a lucrative region. Major players like Thermo Fisher Scientific, Illumina, and QIAGEN are driving innovation in this field.

Market Dynamics: Drivers & Restraints

Rising Adoption of Precision Medicine

The global multiomics market is driven by the growing focus on precision medicine, which allows for a deeper understanding of individual genetic, proteomic, and metabolic profiles. Governments and healthcare organizations are investing heavily in multiomics research to develop personalized therapies for complex diseases like cancer and neurological disorders. The integration of artificial intelligence and bioinformatics accelerates drug discovery and patient-specific treatment strategies.

For instance, in January 2025, Enhanc3D Genomics, a pioneer in 3D genomics technology, launched a suite of integrated multi-omics solutions to enhance drug discovery precision. The solutions, based on the company's proprietary 3D genomics platform, provide partners with a comprehensive end-to-end solution to support decision-making throughout the drug discovery and development process.

Data Complexity and Integration

The global multiomics market faces challenges due to data complexity and integration, as it generates vast heterogeneous data from genomics, transcriptomics, proteomics, and metabolomics. This requires advanced computational tools for meaningful interpretation, standardization across platforms, and interoperability between databases. Ensuring data accuracy, reproducibility, and scalability requires high-performance computing and sophisticated algorithms, which limits accessibility for smaller research organizations and clinical applications.

Segment Analysis

The global multi-omics market is segmented based on product & service, technology, application, end-user, and region.

Product & Service:

The instruments from the product & service segment are expected to dominate the multi-omics market with the highest market share.

Multiomics instruments, including NGS platforms, mass spectrometers, and microarrays, are specialized lab equipment used in various omics fields for precise detection, quantification, and characterization of biological molecules, enabling high-throughput data generation and drug development.

Instruments are vital in the global multiomics market, enabling precise analysis of biological molecules in genomics, transcriptomics, proteomics, and metabolomics. Advanced sequencing platforms, mass spectrometers, chromatography systems, and imaging technologies generate high-resolution data, facilitating molecular profiling, biomarker discovery, and disease mechanism studies. Continuous innovations in automation, miniaturization, and high-throughput analysis improve efficiency and accessibility, making multiomics technologies more accessible for research institutes, biotechnology companies, and clinical laboratories.

For instance, in June 2024, Mission Bio launched the Tapestri Single-cell Multiple Myeloma Multiomics Solution, a product suite designed to revolutionize multiple myeloma research and therapeutic development. The suite offers comprehensive insights into disease evolution and biology at the single-cell level, enabling researchers and drug developers to understand therapy resistance and disease relapse at the subclonal level. This new product suite will enhance the understanding of disease progression and treatment resistance.

Geographical Analysis

North America is expected to hold a significant position in the multi-omics market with the highest market share

North America leads the global multi-omics market due to its significant product launches, robust research infrastructure, government funding, and key industry players. The region's biotechnology and pharmaceutical sectors invest in multi-omics technologies for drug discovery, precision medicine, and clinical diagnostics. Advanced sequencing platforms, bioinformatics tools, and AI-driven analytics enhance research capabilities.

For instance, in September 2024, The Translational Genomics Research Institute (TGen), part of the City of Hope, launched the Center for Spatial Multi-Omics (COSMO), a service center aimed at transforming biomedical research through spatial biology. COSMO offers services to visualize and map molecular data at the single-cell level within tissues, preserving important cellular environments and structures for histological analysis. Advanced technologies enable researchers to examine thousands of RNA targets in detail.

Moreover, partnerships and collaborations between academic institutions and biotech firms accelerate innovation which indeed helps the region to grow during the forecast period. For instance, in January 2024, Thermo Fisher Scientific Inc. and Akoya Biosciences signed a license and distribution agreement to provide a comprehensive solution for spatial multi-omics workflows, simplifying the whole-slide, multi-omics imaging process and examining protein and RNA, crucial for cancer research fields.

Furthermore, in January 2024, BD partnered with Hamilton Company to create robotics-compatible and automated reagent kits for large-scale single-cell multi-omics experiments, aiming to standardize and minimize human error.

Competitive Landscape

The major global players in the multi-omics market include BD (Becton, Dickinson, and Company), Thermo Fisher Scientific Inc., Illumina, Inc., Danaher Corporation, Bruker Corporation, QIAGEN N.V, Agilent Technologies, Inc., Genedata, Shimadzu Corporation, and Element Biosciences among others.

Key Developments

  • In May 2024, QIAGEN launched its QIAseq Multimodal DNA/RNA Library Kit, which enables the preparation of DNA and RNA libraries for next-generation sequencing, including whole genome sequencing and whole transcriptome sequencing, and downstream target enrichment using hybrid-capture from a single sample.
  • In June 2023, Singleton, a trusted partner for scientists and clinicians, launched two new single-cell multi-omics products: NEO and Python Junior. These portable instruments are designed to fit into any laboratory and deliver accurate and reproducible results. The NEO library processing system and Python Junior tissue dissociation instrument aim to make single-cell sequencing accessible for every laboratory, ensuring accurate and reproducible results for researchers and clinicians alike.

Why Purchase the Report?

  • Technological Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global multi-omics market report delivers a detailed analysis with 70 key tables, more than 65 visually impactful figures and 159 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Application & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

  • 1.1. Objectives of the Report
  • 1.2. Report Coverage & Definitions
  • 1.3. Report Scope

2. Executive Insights and Key Takeaways

  • 2.1. Market Highlights and Strategic Takeaways
  • 2.2. Key Trends and Future Projections
  • 2.3. Snippet by Product & Service
  • 2.4. Snippet by Technology
  • 2.5. Snippet by Application
  • 2.6. Snippet by End-User
  • 2.7. Snippet by Region

3. Dynamics

  • 3.1. Impacting Factors
    • 3.1.1. Drivers
      • 3.1.1.1. Rising Adoption of Precision Medicine
      • 3.1.1.2. Advancements in Sequencing Technologies
    • 3.1.2. Restraints
      • 3.1.2.1. Data Complexity and Integration
      • 3.1.2.2. Regulatory and Ethical Concerns
    • 3.1.3. Opportunity
      • 3.1.3.1. Development of Cloud-Based Multi-omics Solutions
    • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

  • 4.1. Market Leaders and Pioneers
    • 4.1.1. Emerging Pioneers and Prominent Players
    • 4.1.2. Established leaders with largest largest-selling Brand
    • 4.1.3. Market leaders with established Product
  • 4.2. CXO Perspectives
  • 4.3. Latest Developments and Breakthroughs
  • 4.4. Case Studies/Ongoing Research
  • 4.5. Regulatory and Reimbursement Landscape
    • 4.5.1. North America
    • 4.5.2. Europe
    • 4.5.3. Asia Pacific
    • 4.5.4. Latin America
    • 4.5.5. Middle East & Africa
  • 4.6. Porter's Five Force Analysis
  • 4.7. Supply Chain Analysis
  • 4.8. Patent Analysis
  • 4.9. SWOT Analysis
  • 4.10. Unmet Needs and Gaps
  • 4.11. Recommended Strategies for Market Entry and Expansion
  • 4.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 4.13. Pricing Analysis and Price Dynamics
  • 4.14. Key Opinion Leaders

5. By Product & Service

  • 5.1. Introduction
    • 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product & Service
    • 5.1.2. Market Attractiveness Index, By Product & Service
  • 5.2. Instruments*
    • 5.2.1. Introduction
    • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 5.3. Consumables & Reagents
  • 5.4. Services

6. By Technology

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 6.1.2. Market Attractiveness Index, By Technology
  • 6.2. Genomics*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Transcriptomics
  • 6.4. Proteomics
  • 6.5. Metabolomics
  • 6.6. Epigenomics

7. By Application

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 7.1.2. Market Attractiveness Index, By Application
  • 7.2. Drug Discovery & Development*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Precision Medicine
  • 7.4. Clinical Diagnostics
  • 7.5. Biotechnology & Industrial Applications

8. By End-User

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.1.2. Market Attractiveness Index, By End-User
  • 8.2. Pharmaceutical & Biotechnology Companies*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Research Institutes & Academic Centers
  • 8.4. Hospitals & Clinics
  • 8.5. CROs & CDMOs

9. Regional Market Analysis and Growth Opportunities

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product & Service
    • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.2.7.1. U.S.
      • 9.2.7.2. Canada
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product & Service
    • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.3.7.1. Germany
      • 9.3.7.2. U.K.
      • 9.3.7.3. France
      • 9.3.7.4. Spain
      • 9.3.7.5. Italy
      • 9.3.7.6. Rest of Europe
  • 9.4. Latin America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product & Service
    • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.4.7.1. Mexico
      • 9.4.7.2. Brazil
      • 9.4.7.3. Argentina
      • 9.4.7.4. Rest of Latin America
  • 9.5. Asia-Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product & Service
    • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.5.7.1. China
      • 9.5.7.2. India
      • 9.5.7.3. Japan
      • 9.5.7.4. South Korea
      • 9.5.7.5. Rest of Asia-Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product & Service
    • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

10. Competitive Landscape and Market Positioning

  • 10.1. Competitive Overview and Key Market Players
  • 10.2. Market Share Analysis and Positioning Matrix
  • 10.3. Strategic Partnerships, Mergers & Acquisitions
  • 10.4. Key Developments in Product Portfolios and Innovations
  • 10.5. Company Benchmarking

11. Company Profiles

  • 11.1. BD (Becton, Dickinson and Company) *
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio
      • 11.1.2.1. Product Description
      • 11.1.2.2. Product Key Performance Indicators (KPIs)
      • 11.1.2.3. Historic and Forecasted Product Sales
      • 11.1.2.4. Product Sales Volume
    • 11.1.3. Financial Overview
      • 11.1.3.1. Company Revenue's
      • 11.1.3.2. Geographical Revenue Shares
      • 11.1.3.3. Revenue Forecasts
    • 11.1.4. Key Developments
      • 11.1.4.1. Mergers & Acquisitions
      • 11.1.4.2. Key Product Development Activities
      • 11.1.4.3. Regulatory Approvals, etc.
    • 11.1.5. SWOT Analysis
  • 11.2. Thermo Fisher Scientific Inc
  • 11.3. Illumina, Inc
  • 11.4. Danaher Corporation
  • 11.5. Bruker Corporation
  • 11.6. QIAGEN N.V
  • 11.7. Agilent Technologies, Inc
  • 11.8. Genedata
  • 11.9. Shimadzu Corporation
  • 11.10. Element Biosciences

LIST NOT EXHAUSTIVE

12. Assumption and Research Methodology

  • 12.1. Data Collection Methods
  • 12.2. Data Triangulation
  • 12.3. Forecasting Techniques
  • 12.4. Data Verification and Validation

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us